By August Graham, PA & Rom Preston-Ellis The competition watchdog has found that women needing hormone replacement therapy (HRT) might see higher prices if a deal between two businesses is allowed to go ahead. The Competition and Markets Authority (CMA) said that an initial investigation had found that the plan for Theramex to buy the European rights to two drugs could reduce competition. Last year, the London-based women’s health company said it would buy the rights to Duphaston and Femoston HRT from US company Viatris. Theramex is already one of the largest players in the UK’s market for “sy…